COVID-19 Induced Telogen Effluvium

NCT ID: NCT04834102

Last Updated: 2021-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-27

Study Completion Date

2021-04-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Telogen effluvium (TE) is one of the most common causes of non-scarring alopecia. During the COVİD-19 pandemic, there is an increased number of Telogen effluvium patients.This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection and correlation between the severity of covid-19 and TE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Telogen Effluvium SARS-CoV Infection Alopecia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Tests

Evaluation of blood ferritin, hemoglobine, serum iron and serum iron binding capacity

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sars-CoV-2 infection in the past year

Exclusion Criteria

* Other common causes of Telogen effluvium ( such as anemia, iron deficiency, thyroid dysfunction)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istanbul Medeniyet University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hasan Aksoy

Specialist Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hasan AKSOY, Dr.

Role: PRINCIPAL_INVESTIGATOR

Istanbul Medeniyet University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istanbul Medeniyet University

Istanbul, Kadıköy, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Umut Mert YILDIRIM, Dr.

Role: CONTACT

+905423383842

Hasan AKSOY, Dr.

Role: CONTACT

+905053005460

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Umut Mert YILDIRIM, Dr.

Role: primary

+905423383842

Hasan Aksoy, Specialist Dr.

Role: backup

+905053005460

References

Explore related publications, articles, or registry entries linked to this study.

Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 2020 May 27;12(5):e8320. doi: 10.7759/cureus.8320.

Reference Type RESULT
PMID: 32607303 (View on PubMed)

Mieczkowska K, Deutsch A, Borok J, Guzman AK, Fruchter R, Patel P, Wind O, McLellan BN, Mann RE, Halverstam CP. Telogen effluvium: a sequela of COVID-19. Int J Dermatol. 2021 Jan;60(1):122-124. doi: 10.1111/ijd.15313. Epub 2020 Nov 23. No abstract available.

Reference Type RESULT
PMID: 33226117 (View on PubMed)

Rizzetto G, Diotallevi F, Campanati A, Radi G, Bianchelli T, Molinelli E, Mazzanti S, Offidani A. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2021 Jan;34(1):e14547. doi: 10.1111/dth.14547. Epub 2020 Nov 23.

Reference Type RESULT
PMID: 33190397 (View on PubMed)

Cline A, Kazemi A, Moy J, Safai B, Marmon S. A surge in the incidence of telogen effluvium in minority predominant communities heavily impacted by COVID-19. J Am Acad Dermatol. 2021 Mar;84(3):773-775. doi: 10.1016/j.jaad.2020.11.032. Epub 2020 Dec 10. No abstract available.

Reference Type RESULT
PMID: 33310111 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021/0123

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

New Treatment of Alopecia Areata
NCT05594316 COMPLETED NA